
Maya Uccheddu lives with myasthenia gravis and has experienced how hormonal changes can shape life with the disease. She highlights how menstruation, perimenopause and menopause remain under-discussed in neurological care and calls for hormonal life stages to be accounted for in research, clinical conversations and guidelines.
Parkinson disease (PD) is a heterogeneous neurodegenerative disorder characterized by variable progression and treatment response. Over the past three decades, genetic discoveries have reshaped our understanding of PD biology, identifying rare monogenic forms, strong genetic risk variants and a large set of common and rare genetic variants variably contributing to PD heritability. These findings led to the identification of key pathways implicated in the neurodegenerative process, including protein misprocessing, lysosomal and mitochondrial impairment, and altered immune response. In this Review, we describe the evolution of PD genetics and discuss its current clinical impact and future role in shaping precision medicine, from diagnosis and prognosis to the development of disease-modifying therapies. Genetic information is increasingly used to support clinical decision-making, improve patient counselling and identify biologically distinct forms of PD. Importantly, genetic insights are driving therapeutic innovation, enabling targeted strategies and genetically stratified clinical trials. Despite ongoing challenges such as incomplete penetrance, variable expression of disease and missing heritability across multiple ancestries, integrating genetic knowledge into research and clinical practice is accelerating the transition towards precision medicine in PD, providing a framework for more personalized care and improved patient outcomes. Genetic discoveries in Parkinson disease (PD), from rare monogenic mutations to common risk variants, have clarified key determinants of disease risk and variability. This Review highlights the evolution of PD genetics, its current clinical relevance for diagnosis, counselling and therapeutic management, and its future role in enabling patient stratification and advancing precision medicine approaches in PD.
The novel Bruton’s tyrosine kinase inhibitor remibrutinib is superior to the established disease-modifying drug teriflunomide for reducing relapse rates in people with multiple sclerosis, according to recently released phase III trial data.
Monocytes and macrophages originating from cranial bone marrow drive persistent neuroinflammation in chronic traumatic brain injury, new research suggests.
Phase I trial data presented at MSToronto2026 indicate that the chimeric antigen receptor (CAR) T cell therapy azercabtagene zapreleucel (azer-cel) is safe and has the potential to improve outcomes in people with progressive multiple sclerosis.